Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Assets (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Current Assets for 14 consecutive years, with $198.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 25.9% year-over-year to $198.7 million, compared with a TTM value of $198.7 million through Dec 2025, down 25.9%, and an annual FY2025 reading of $204.3 million, down 31.85% over the prior year.
  • Current Assets was $198.7 million for Q4 2025 at Enanta Pharmaceuticals, down from $204.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $448.5 million in Q2 2023 and bottomed at $198.7 million in Q4 2025.
  • Average Current Assets over 5 years is $312.6 million, with a median of $312.4 million recorded in 2022.
  • The sharpest move saw Current Assets soared 43.26% in 2023, then tumbled 36.1% in 2024.
  • Year by year, Current Assets stood at $327.0 million in 2021, then fell by 13.23% to $283.7 million in 2022, then surged by 37.57% to $390.3 million in 2023, then plummeted by 31.3% to $268.1 million in 2024, then decreased by 25.9% to $198.7 million in 2025.
  • Business Quant data shows Current Assets for ENTA at $198.7 million in Q4 2025, $204.3 million in Q3 2025, and $222.7 million in Q2 2025.